Name Gregg W. Stone
Country United States
Job Interventional Cardiologist

Other summitMD.com content(s) by This Presenter

  1. Paclitaxel-Eluting TAXUS Stents Strengths and Weaknesses
  2. Recent Updates from the Taxus Trials (Taxus 2 and 4 Late FU, Taxus Meta-Analysis, and Taxus 5)
  3. Zen Philosophy - The KEY to CTO Success
  4. Evidence-Based Medicine Analysis of Current DES Clinical
  5. EMERALD Trial: Lessons Learned
  6. Optimizing Outcomes of Primary PCI: From CADILLAC to HORIZONS
  7. Taxus V Clinical Update
  8. Evidence-Based Medicine Analysis of Current DES Clinical Use Guidelines: A Roadmap for Clinicians
  9. 2007 Guidelines Update for DES: An Evidence-Based Medicine Critical Analysis
  10. Should DES Use be Reduced Due to Safety Concerns? Important Messages from the Randomized DES Trials
  11. The Baseline Clinical Features and Plaque Characteristics from the PROSPECT Trial
  12. ACUITY PCI: A Prospective Trial of Patients With Acute Coronary Syndromes Undergoing PCI After Randomization to Heparin Plus Glycoprotein IIb/IIIa Inhibitors vs Bivalirudin With or Without Glycoprotein IIb/IIIa Inhibitors: 30-Day Clinical and Angiographic Core Laboratory Results
  13. SPIRIT-III: Clinical, Angiographic and IVUS Results from the Pivotal United States Randomized SPIRIT-III Trial of the Xience V Everolimus Eluting Coronary Stent System in Patients With Coronary Artery Disease
  14. Taking the Evidence-Based Approach to ACS: Examination of New Antithrombin Trial Data
  15. SPIRIT III (US Pivotal Study Results for Xience V Everolimus Eluting Coronary Stent)
  16. Bivalirudin for the Best Overall Outcomes and Most Cath Lab Compatible
  17. COOL RCN : Randomized Trail of Systemic Hypothermia for Prevention of Radiocontrast Nephropathy
  18. HORIZONS AMI AMI: Prospective Randomized Trials of Paclitaxel-Eluting Stents vs. BMS in Patients with STEMI
  19. HORIZONS AMI: Implications for Pharmaco-Adjunctive Therapy and DES Use
  20. Revived Indications for Thrombus Aspiration During Primary PCI: Unanswered Questions after TAPAS
  21. New Paradigms of Care for ST-Elevation Myocardial Infarction (STEMI): Focusing on Mortality and Attributable Death Analysis in Cath-Based Care: What Do Device and Drug Trials Teach Us?
  22. Comparison of DES versus BMS in Real World Registries
  23. HORIZONS AMI: A Large Prospective Randomized Trial of PES vs. BMS in Patients with STEMI
  24. Linkage of Current Plaque Vulnerability to Future Events: Evidence from PROSPECT Study
  25. STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Weight Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel, and Prasugrel)
  26. The Latest Updates in DES Clinical Data
  27. Introducing EXCEL: The \"Definitive\" Unprotected Left Main Randomized Trial!
  28. Does PROSPECT Support the Use of Invasive Imaging to Diagnose and Treat Vulnerable Plaque with DES?
  29. Milestone for Left Main PCI: Upcoming Excel LM Trial
  30. Bioabsorble or Free-Polymer DES: Current and New Technologies
  31. Motivation, Objective and Implication of EXCEL Study
  32. DES in Left Main Disease: New Guidelines and Updates from EXCEL
  33. The EXCEL Trial
  34. Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease (SPIRIT IV)
  35. Xience Platform Safey Update
  36. PLATINUM Workhorse Data from ACC
  37. What¡¯s Known and Unknown about LM PCI: Transitioning from SYNTAX to EXCEL
  38. PCI Today: Best Practices, Optimal Outcomes, and Limitations: When Do I Prefer CABG for MVD?
  39. Latest Update of PLATINUM Trial: Promus Element Workhorse Two Year Follow-up
  40. New Insights Regarding the Safety and Efficacy of DAPT After Stenting
  41. Current Status of EXCEL Study
  42. Reduction of Thrombus: Routine vs. Selective Aspiration
  43. Evidence-based Pharmacotherapy for ACS Patients: The Forest and the Trees
  44. Lessons from the Pooled Data using Xience Everolimus-eluting Stent
  45. Bioresorbable Scaffolds in a "Nutshell": Updates and Expectations
  46. Vulnerable Plaque Detection and Treatment: PROSPECT II and PROSPECT ABSORB
  47. Future Roadmap of the Mitral Valve Therapies
  48. Focal Treatment of Vulnerable Plaque: Stents, Scaffolds and Prospect II
  49. UFH Versus Bivalirudin: Which One Should I Use?
  50. Evolution, BVS Unique Benefits, Clinical Perspectives on Angina
  51. PLATO: Impact on the Management of ACS and Personalizing Treatment with Ticagrelor
  52. Left Main PCI: Anticipating EXCEL
  53. BRS: From ABSORB III to the Future
  54. Management of Stable Coronary Heart Disease with Objective Ischemia: COURAGE, FAME2 and Recent Meta-Analysis
  55. Drug-Eluting Stents vs. Bioresorbable Vascular Scaffolds: Is Newer Better?  
  56. ABSORB III - Current and Future Use of Bioresorbable Scaffolds
  57. Why Do We Need a Fully Bioresorbable Vascular Scaffold; From Absorb III and ABSORB Meta-Analysis to the Future
  58. The Future PROSPECT for the Role of Antiplatelet Therapy
  59. [Satellite Lecture]Congratulatory Remark & Keynote Lecture: ¡°Left Main Intervention Comes of Age: A 40-Year Odyssey from Balloon Angioplasty to Drug-Eluting Stents¡±
  60. [Satellite Lecture] PCI Outcomes with Bioresorbable Scaffolds: Role of Technique and DAPT
  61. Clinical Trials in Functional Mitral Regurgitation
  62. ABSORB III, IV, Updated Meta, and More - Expert Future Expectation on Bioabsorbable Scaffolds
  63. ABSORB IV: 30-day Outcomes from a Randomized Trial of a Bioresorbable Scaffold Versus a Metallic DES in Patients with Coronary Artery Disease
  64. XIENCE Safety ; Review of XIENCE DAPT Clinical Evidence and Clinical Program
  65. Future Perspectives of BRS, Will It Go Forward or Not?
  66. Inter-Atrial Shunts in HF: Devices, Indication, and Outcomes
  67. COAPT
  68. FFRCT to Guide Revascularization Decisions: The DECISION Trial
  69. Long-term Outcomes and More Data from ABSORB Trials
  70. Deep Dive into Mitraclip Trials for Functional MR
  71. The COAPT Trial: How the Trial Succeed?
  72. ONYX One and ONYX One CLEAR Trials of 1-month DAPT After Onyx
  73. Long-term and Updated Data from EXCEL and NOBLE
  74. Mitral Valve: Future Perspectives
  75. EXCEL Trial: Extended Long-term and Key Clinical Substudies
  76. New Insights from the COAPT: Patient Eligibility and Timing